Results

Total Results: 2,231 records

Showing results for "disease".

241. Executive Summary_Comparative Effectiveness Review No. 273_Treatment of Stages I-III Squamous Cell Anal Cancer: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-273-anal-cancer-executive-summary.pdf
     August 01, 2024 - doublet chemoradiation (CRT) with 5-fluorouracil (5FU) plus mitomycin (MMC) likely results in greater disease-free … • Compared with concurrent CRT with 5FU, CRT with 5FU plus MMC may result in greater disease-free … with capecitabine plus MMC, CRT with paclitaxel plus capecitabine plus MMC showed greater overall, disease … Moderate Disease-specific mortality (up to 5 yrs) 1; RCT; n=585 CRT favored over RT alone; rate … Low Disease-free survival (up to 3 yrs) 1; RCT; n=144 Significantly greater in the paclitaxel arm

242. Data-Points 2 Diabetic-Foot-Ulcers Data 02-2011 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/data-points_2_diabetic-foot-ulcers_data_02-2011.pdf
     January 01, 2011 - Beneficiaries, 2006-2008, by Age, Gender, and Race, and Broken Down by Diagnosis of Peripheral Artery Disease … Alaska Native 2006 6.9% 17.9% 5.0% Total All 2007 6.0% 13.2% 4.0% Age Disabled/end stage renal disease … Alaska Native 2007 6.8% 17.5% 4.9% Total All 2008 6.0% 13.1% 3.9% Age Disabled/end stage renal disease … With Diabetes and Without PAD Total All 2006 0.5% 2.1% 0.053% Age Disabled/end stage renal disease … 2.08% 2.07% 1.93% 1.55% Total All 2008 1.70% 1.78% 1.70% 1.43% Age† Disabled/end stage renal disease

243. Mortality Risk in Chronic Obstructive Pulmonary Disease Patients Using Theophylline | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/copd-management/research

244. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/decide16final-mortality-risk-in-copd-pts-using-theophylline.pdf
     December 01, 2009 - Mortality risk in chronic obstructive pulmonary disease patients using theophylline. … disease (PUD), gastroesophogeal reflux disease (GERD), arrhythmias, depression, hypertension, ischemic … A 4-year trial of tiotropium in chronic obstructive pulmonary disease. … The use of theophylline in chronic obstructive pulmonary disease. … Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.

245. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-management_research.pdf
     December 01, 2009 - Mortality risk in chronic obstructive pulmonary disease patients using theophylline. … disease (PUD), gastroesophogeal reflux disease (GERD), arrhythmias, depression, hypertension, ischemic … A 4-year trial of tiotropium in chronic obstructive pulmonary disease. … The use of theophylline in chronic obstructive pulmonary disease. … Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.

246. Plasma-Cell-Dyscrasias-Sflc-Assay Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/plasma-cell-dyscrasias-sflc-assay_executive.pdf
     August 01, 2012 - monitoring.8,11 The SFLC assay may also be the only means of detecting a disease marker in some disease … disease settings, and their results need to be evaluated with this in mind. … as well as different disease populations. … Finally, variation in disease severity studied can lead to spectrum bias. … of disease (e.g., response to treatment, relapse, or light chain escape).

247. Data Points 13: Use of Preoperative Breast MRI among older women with ductal carcinoma in situ and locally invasive breast cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-mri-utilization_research.pdf
     August 01, 2012 - increased dramatically from 2002 to 2007 for both women with DCIS (<1% to 12.9%) and with invasive disease … Specifically, we included International Classification of Diseases for Oncology, Third Edition (ICD-O … Among women with invasive cancer, rates of MRI use de- creased with higher grade disease. … The increase was observed for both women with DCIS and early invasive disease. … ) received more MRIs prior to surgery than those with lower risk disease.

248. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
     January 24, 2022 - : 3 (8.6) Cardiovascular disease: 4 (11.4) CKD: 1 (2.9) Chronic lung disease: 3 (8.6) CMIA ELISA Abbott … ) Pulmonary disease: 2 (12.5) Heart disease: 2 (12.5) CLIA IgG, IgM ManglumiTM 2019 nCovIgM and the MaglumiTM … controlled cohort 10 HIV Adult COVID-19 patients who were hospitalized in the Department of Infectious Diseases … 2020 - 11/30/2020 COVID-19 patients >18 yrs old who were hospitalized in the Department of Infectious Diseases … patients) The Transplant Institute, Sahlgrenska University Hospital, and the Department of Infectious Diseases

249. Ch 6-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_6-user-guide-to-ocer_130129.pdf
     October 30, 2012 - such as in cancer or H5N1 influenza; or to manage or reduce the burden of chronic diseases including … diabetes, psoriasis, Parkinson’s disease, and depression. … only six items.34 In contrast, other popular measures focus on symptoms that are affected by many diseases … Statistical validation of intermediate endpoints for chronic diseases. … The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal

250. Restless-Legs Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs_research-protocol.pdf
     December 16, 2011 - and Objectives for the Systematic Review Overview Restless legs syndrome (RLS) or Willis-Ekbom disease … If the disease progresses, symptoms may occur earlier in the day and intensify even further at night … are used to assess disease severity and treatment- induced changes in disease status. … Yet, the disease is chronic, often requiring life-long treatment. … and definition of clinically significant change in disease status used in individual studies.

251. Dyspnea DEcIDE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dyspnea_research.pdf
     April 01, 2010 - requires valid, reliable, and responsive measures of the care provided to patients across settings and diseases … review of over 5000 titles in Western literature for quality measures of symptom management across diseases … care measure set.17 The dyspnea measure evaluates the proportion of patients with advanced chronic diseases … VAS were felt by panelists to be appropriate for clinical dyspnea assessment in chronic progressive diseases … Descriptors of breathlessness in cardiorespiratory diseases.

252. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_research-protocol.pdf
     March 09, 2010 - arthritis (JIA), formerly known as juvenile rheumatoid arthritis, is the most common rheumatologic disease … with more destructive joint disease … Evaluating changes in JIA disease status can be challenging. … First, these measures evaluate relative and not absolute changes in disease progression. … Effects of Omega-3 Fatty Acids on Cardiovascular Disease.

253. Draft Comparative Effectiveness Review Appendicies (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-artery-stenosis_appendixes.pdf
     April 01, 2005 - Imaging test: Laboratory test: Clinical exam test: Demographics: Concurrent diseases … Survival in renal vascular disease. … Surgery for renovascular diseases: a single-center experience in revascularizing renal artery stenosis … HTN and CKD • Populations had ≥60% to ≥80% stenosis • Populations had unilateral and bilateral diseases … that bilateral versus unilateral disease did not predict progressive kidney disease

254. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0277_03-10-2008.pdf
     January 01, 2008 - HSCTs are used to treat both malignant and non-malignant diseases in children. … HSCT is associated with high morbidity and mortality in all ages and all diseases. … Factors that impact the appropriateness and success of any HSCT include the stage and/or severity of the disease … ), there is a large body of literature regarding HSCT across many diseases. … The diseases covered in the AHRQ review will be defined during the refinement phase.

255. Appendix K Rapid Evidence Review Treatments for Clostridium difficile Colitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/clinical-pathway-methods-report-appendix-k.pdf
     February 01, 2018 - Australasian Society of Infectious Diseases 20164 Oral antibiotic treatment – nonsevere disease … ; FMT: Fecal microbiota transplantation; ID: infectious disease; SHEA/IDSA: Infectious Diseases Society … Debast SB, Bauer MP, Kuijper EJ, Committee Centre for Infectious Diseases. … Definitions of Disease Severity by Guideline Organization Definitions Infectious Diseases Society of … Australasian Society of Infectious Diseases 20164 CDI: A + (B or C) A.

256. Arthritis-Psoriatric Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
     April 01, 2012 - The condition is associated with the skin disease psoriasis, but not all people with psoriasis will … Additionally, PsA may predate the development of skin disease, leading to some diagnostic uncertainty … Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs or … Analytic framework for treatment for psoriatic arthritis DMARDS = disease-modifying antirheumatic … * American College of Rheumatology measure of disease activity: response scores based on 20, 50, or

257. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-update_research-protocol.pdf
     May 07, 2010 - extensively for treatment of hypertension, heart failure, myocardial infarction, diabetes, and renal disease … disease or events, symptomatic coronary artery disease, end-stage renal disease, quality of life, … , and cerebrovascular disease- specific) o Morbidity (cardiac events [MI], heart failure, cerebral … vascular disease or events [including stroke], symptomatic coronary artery disease, end-stage renal … disease, peripheral vascular disease [as clinically manifest, not markers of], quality of life)

258. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/plasma-cell-dyscrasias-sflc-assay-future_research.pdf
     September 01, 2012 - monitoring.3,6 The SFLC assay may also be the only means of detecting a disease marker in some disease … o Studies of only patients with disease reflects the extreme end of the spectrum of disease severity … 1 *Polyclonal gammopathy is seen in a diverse range of inflammatory and neoplastic diseases where clonal … Poor, since PCD is a rare disease. … 1 *Polyclonal gammopathy is seen in a diverse range of inflammatory and neoplastic diseases where clonal

259. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-2007_executive.pdf
     January 01, 2007 - extensively for treatment of hypertension, heart failure, myocardial infarction, diabetes, and renal disease … disease-specific mortality) and morbidity (cardiac events [myocardial infarction], heart failure, cerebral … vascular disease or events [including stroke], symptomatic coronary artery disease, end stage renal … disease, peripheral vascular disease, and quality of life). 4Safety outcomes considered were overall … (either based on creatinine, GFR, or renal disease) proteinuria).

260. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
     March 01, 2012 - , CHF with or without preserved LV function, diabetes, peripheral arterial disease, chronic kidney disease … disease, or chronic kidney disease) on ACEI/ARB/DRI effectiveness or harms in patients with hypertension … disease, prior coronary revascularization; single- vs. multi-vessel coronary artery disease) on ACE-I … , peripheral vascular disease, diabetes, chronic kidney disease, or congestive heart failure. … ICD-9 (International Classification of Diseases, Ninth Revision) and CPT (Current Procedural Terminology